Chemistry:Peficitinib
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
Trade names | Smyraf |
Other names | ASP015K; JNJ-54781532 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C18H22N4O2 |
Molar mass | 326.400 g·mol−1 |
3D model (JSmol) | |
| |
|
Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).[1][2]
Peficitinib was approved for use in Japan in 2019.[3]
References
- ↑ "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate". Arthritis & Rheumatology 69 (4): 709–719. April 2017. doi:10.1002/art.39955. PMID 27748083.
- ↑ "Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis". Arthritis & Rheumatology 69 (5): 932–942. May 2017. doi:10.1002/art.40054. PMID 28118538.
- ↑ "Peficitinib: First Global Approval". Drugs 79 (8): 887–891. June 2019. doi:10.1007/s40265-019-01131-y. PMID 31093950.
Original source: https://en.wikipedia.org/wiki/Peficitinib.
Read more |